Page 5 of 8 – SEC Filing
ITEM 1. SECURITY AND ISSUER
Item 1 of the Original Schedule 13D (as defined below) is amended and supplemented as follows:
This first amendment to Schedule 13D (Amendment No. 1) relates to the Common Stock, par value $0.0001
per share (the Shares) of Corindus Vascular Robotics, Inc., a Delaware corporation (the Issuer), and supplements the information set forth in the Schedule 13D filed on March 10, 2017 (the Original
Schedule 13D and together with this Amendment No.1, the Schedule 13D). The principal executive offices of the Issuer are located at 309 Waverley Oaks Road, Suite 105, Waltham, MA 02452.
The Reporting Persons (as defined below) beneficially own an aggregate of 26,861,154 Shares (the Subject Shares), including
(i) 11,336,154 Shares, (ii) 10,800,000 Shares issuable upon the conversion of 540,000 shares of the Issuers Series A Convertible Preferred Stock (the Series A Preferred Stock) and (iii) 4,725,000 Shares issuable upon the
exercise of warrants (the Warrants). The Subject Shares represent approximately 14.2% of the issued and outstanding Shares, after giving effect to the conversion of the Series A Preferred Stock and the exercise of the Warrants,
and based upon 188,772,869 Shares outstanding as of March 15, 2018 as reported by the Issuer on March 16, 2018.
ITEM 2. IDENTITY AND
BACKGROUND
Item 2 of the Original Schedule 13D is amended and restated as follows:
(a) This statement is being filed by Hudson Executive Capital LP, a Delaware limited partnership (Hudson Executive), HEC
Management GP LLC, a Delaware limited liability company (Management GP), and Douglas L. Braunstein (together with Hudson Executive and Management GP, the Reporting Persons).
(b) The principal business address of the Reporting Persons is c/o Hudson Executive Capital LP, 570 Lexington Avenue, 35th Floor, New
York, NY 10022.
(c) Hudson Executives principal business is to serve as investment advisor to certain affiliated investment funds
(the HEC Funds). Management GPs principal business is to serve as the general partner of Hudson Executive. The principal occupation of Mr. Braunstein is to serve as the Managing Partner of Hudson Executive and the
Managing Member of Management GP.
(d) None of the Reporting Persons, nor any of their officers or managing directors, have during the last
five years been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) None of the Reporting
Persons, nor any of their officers or managing directors, have during the last five years been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining
future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.
(f) Hudson Executive is a Delaware limited partnership. Management GP is a Delaware limited liability company. Mr. Braunstein is a citizen
of the United States.
ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION
Item 3 of the Original Schedule 13D is hereby amended and supplemented as follows:
The Reporting Persons caused one of the HEC Funds to use its working capital to purchase the Series A Preferred Stock and the Warrants
reported herein (the Purchased Securities), in the private placement described in Items 5 and 6 of this Schedule 13D. The total purchase price for the Purchased Securities was $13,500,000.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER
Item 5
of the Original Schedule 13D is amended and restated as follows:
